Symbols

ATYR

aTyr Pharma·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ATYR

Atyr Pharma, Inc.

A company that focused on researching the extracellular functionality and signaling pathways of tRNA synthetases

Industry

Biological Technology

Established Date

09/08/2005

Listing Date

05/07/2015

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.atyrpharma.com

Security Type

Common stock

Office address

10240 Sorrento Valley Road, Suite 300, San Diego, CA 92121

Business

Introduction

ATyr Pharma, Inc., was incorporated in Delaware on September 8, 2005. The company is a clinical-stage biotechnology company focused on developing therapies for the treatment of fibrosis and inflammation based on tRNA synthetase biology. Its lead drug candidate, efzofitimod, is a novel immunomodulator that is being investigated for the treatment of interstitial lung diseases, including pulmonary sarcoidosis and systemic sclerosis-related interstitial lung diseases.

Company Financials

EPS

ATYR has released its 2025 Q4 earnings. EPS was reported at -0.14, versus the expected -0.18, beating expectations. The chart below visualizes how ATYR has performed over recent quarters, highlighting trends in earnings surprises.